- Previous Close
0.0000 - Open
0.0111 - Bid 0.0150 x --
- Ask 0.0200 x --
- Day's Range
0.0111 - 0.0111 - 52 Week Range
0.0080 - 0.0580 - Volume
10 - Avg. Volume
91,127 - Market Cap (intraday)
1.412M - Beta (5Y Monthly) 0.01
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date May 15, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Avenir Wellness Solutions, Inc., through its subsidiary The Sera Labs, Inc., engages in the development of nutraceutical formulation and delivery technologies in novel dosage forms to improve efficacy and enhance wellness. It provides its products in beauty, health and wellness, and pet care categories under the Seratopical, Seratopical Revolution SeraLabs, and Nutri-Strips brand names. The company sells its products through drug and grocery chains, convenience stores, and mass retailers. It also offers its products under private label to retailers and multi-level marketers, as well as DTC, via online website orders, including opt-in subscriptions. The company was formerly known as CURE Pharmaceutical Holding Corp. and changed its name to Avenir Wellness Solutions, Inc. in October 2022. Avenir Wellness Solutions, Inc. was incorporated in 2014 and is headquartered in Sherman Oaks, California.
www.avenirwellness.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AVRW
View MorePerformance Overview: AVRW
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVRW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVRW
View MoreValuation Measures
Market Cap
1.41M
Enterprise Value
10.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.64
Price/Book (mrq)
--
Enterprise Value/Revenue
5.02
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-134.82%
Return on Assets (ttm)
-107.10%
Return on Equity (ttm)
--
Revenue (ttm)
2.04M
Net Income Avi to Common (ttm)
-2.76M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
11k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
52.38k